Viking, Eli Lilly and Novo Nordisk
Eli Lilly (LLY) Stock Price Prediction and Forecast 2025-2030
Since the start of 2020, Eli Lilly’s (NYSE: LLY) stock price chart has been straight up and to the right, up 519.23% and currently trading at $818.68. The company has been around since 1876 and the stock didn’t go public until 1952 but in the last 4 years,
Is Eli Lilly Stock Headed Toward $1300 Levels?
Eli Lilly has seen a stellar run lately given the very high demand for its obesity drug – Zepbound – which, along with its diabetes drug – Mounjaro – is expected to garner $50 billion in annual peak sales.
Is Eli Lilly Stock a Buy?
Weight loss drugs, primarily GLP-1 agonists, have taken the healthcare industry and the stock market by storm. Leading pharmaceutical company Eli Lilly ( LLY -2.02%) is a significant player in the space, helping explain why the stock has soared 250% over the past three years.
Don’t Fret About Eli Lilly and Novo’s Weight-Loss Drug Rivals, Analyst Says
UBS expects the two to form a duopoly for years to come, predicting ‘limited penetration’ from new entrants until 2029..
Why Viking’s Weight-Loss Drug News Is Weighing on Eli Lilly, Novo Nordisk Stocks
Eli Lilly and Novo Nordisk shares lost ground Thursday, while shares of Viking Therapeutics soared after the company reported advances in trials of its weight-loss drugs that could challenge the dominance of other players.
Missed Out on Eli Lilly? These 2 Healthcare Stocks Have Big Catalysts on the Horizon.
Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer. The Motley Fool reaches millions of people every month through our premium investing solutions, free guidance and market analysis on Fool.com, top-rated podcasts, and non-profit The Motley Fool Foundation.
Viking’s stock pops as obesity-drug contender drags down Eli Lilly, Novo Nordisk
Viking Therapeutics Inc. shares jumped 38% on Thursday after the company signaled progress on an experimental obesity drug that could accelerate its development timeline.
An Ozempic rival is getting closer to market — and it's hurting Novo Nordisk and Eli Lilly stock
Shares of Novo Nordisk and Eli Lilly slid Thursday after San Diego-based Viking Therapeutics announced that it’s advancing an experimental weight loss drug to a late-stage clinical trial.
Viking Therapeutics Unveils Monthly Weight-Loss Shot, And Rocks Eli Lilly, Novo Nordisk
Viking Therapeutics stock rocketed Thursday after the company said it's exploring a monthly dose of its weight-loss drug.
Viking sends Lilly, Novo lower as obesity drug enters late-stage program
Weight loss drugmakers Eli Lilly (NYSE:LLY) and Novo Nordisk (NVO) were among the notable decliners in the premarket Thursday after Viking Therapeutics (NASDAQ:VKTX) announced plans to start a late-stage trial for its obesity candidate VK2735 later this year.
TipRanks on MSN3h
Eli Lilly Wins a New Street-High Price Target
While AI has been the main topic of conversation during the current bull market, the second most discussed item probably ...
Expert Outlook: Eli Lilly and Co Through The Eyes Of 25 Analysts
Analysts have recently evaluated Eli Lilly and Co and provided 12-month price targets. The average target is $930.96, ...
Eli Lilly and Company: The Floodgates To Growth Keep Opening, A Big Win In China
Eli Lilly's stock has surged 88.5% in the past year, driven by weight loss drugs. Check out why I remain neutral on LLY stock ...
Benzinga.com3d
Why Eli Lilly and Company Shares Are Moving Lower On Thursday
Eli Lilly and Company stock is trading lower following competitor Viking's announcement. Viking is advancing the injectable form of VK2735 to Phase 3. The Details: Viking is advancing the ...
Lilly Confirms Date and Conference Call for Second-Quarter 2024 Financial Results Announcement
Eli Lilly and Company (NYSE: LLY) will announce its second-quarter 2024 financial results on Aug. 8, 2024. Lilly will also ...
Daily Reporter6d
Lilly shares slide 7% after Roche announces obesity pill test results
That followed a drop of about 3.8% on Wednesday, after Roche announced preliminary results from a study on its experimental ...
Benzinga.com2d
Analyzing Eli Lilly and Co In Comparison To Competitors In Pharmaceuticals Industry
This could indicate a higher financial risk as the company is more reliant on borrowed funds, and investors may perceive it as a potential concern. For Eli Lilly and Co in the Pharmaceuticals ...